Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Anthera Pharmaceuticals Inc | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2018
ANTHERA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-34637
|
|
20-1852016
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
25801 Industrial Boulevard, Suite B, Hayward,
California
|
|
94545
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 8.01.
|
Other Events.
|
On March 12, 2018, Anthera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing top line data from the Phase 3 RESULT study of Sollpura in patients with exocrine pancreatic insufficiency. A copy of the press release is filed herewith as Exhibit 99.1.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: March 12, 2018
|
Anthera Pharmaceuticals, Inc.
|
|
|
By:
|
/s/ J. Craig Thompson
|
|
|
J. Craig Thompson
|
||
|
President and Chief Executive Officer
(Principal Executive Officer)
|
||
Exhibit Index
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
|